Report Highlights

South Korea Smart Inhalers: Market Overview

The South Korean smart inhalers market reached USD 48.7 million in 2024, shaped overwhelmingly by the country's single-payer National Health Insurance Service (NHIS) framework, which determines device access and commercial viability more directly than consumer preference or clinical demand alone. South Korea's exceptionally high rate of COPD prevalence — estimated at 13.4% among adults over 40 by the Korea Disease Control and Prevention Agency (KDCA) — combined with a government-mandated chronic disease management infrastructure, has created a structurally captive demand base. The private sector's role has been primarily as a supplier into government-defined procurement channels rather than as a demand creator.

Market structure is concentrated, with multinational pharmaceutical companies holding distribution dominance through their existing respiratory drug portfolios, while domestic medical device firms such as Humed and iSens are competing aggressively in the sensor hardware segment. The Ministry of Food and Drug Safety (MFDS) governs device classification, distinguishing between smart inhalers classified as Class II medical devices and software-driven inhaler management applications subject to the Digital Medical Devices Act enacted in 2023. This bifurcated regulatory structure has created separate commercial pathways for hardware and software-as-a-medical-device (SaMD) players, fragmenting the market by approval route rather than therapeutic indication.

Policy-Driven Growth in Smart Inhalers in South Korea

Three specific policy mechanisms are the primary engines of market growth. First, the NHIS's inclusion of smart inhaler sensor add-ons under benefit reimbursement code Z-503, operationalised in 2023, directly subsidises device adoption at the point of care. Under this scheme, patients enrolled in the NHIS Chronic Disease Management Programme (CDMP) receive up to 80% reimbursement on listed devices, reducing the effective cost barrier to near zero for insured patients and compelling hospitals to stock compliant products. The CDMP currently covers approximately 2.3 million registered asthma and COPD patients through 92 designated facilities, each contractually required to offer digital adherence monitoring tools to enrolled patients.

Second, the Ministry of Health and Welfare's Digital Health New Deal, announced in the 2023 government budget with KRW 410 billion in allocated funding through 2027, explicitly targets respiratory disease as a priority category for connected device deployment in public health centres. Third, the Korean government's mandatory transition to electronic prescription records under the Health and Medical Big Data Act requires all prescribing physicians to record inhaler use data in interoperable formats by 2026, creating institutional incentives for hospitals to adopt smart inhalers whose data can feed directly into compliant electronic health record systems. Each of these mechanisms converts policy intent into contractual or financial obligations that translate directly into device procurement.

Regulatory Barriers and Compliance Costs

The MFDS classification system presents the most consequential regulatory barrier. Smart inhalers that incorporate software functions capable of influencing clinical decisions are classified as Class II medical devices under the Medical Device Act (Act No. 16438) and require full pre-market review, a process that averages 18 to 24 months for combination hardware-software products. For devices additionally classified as Digital Medical Devices under the Digital Medical Devices Act (Act No. 17966, effective 2023), a separate SaMD approval track administered by MFDS's Digital Medical Device Division applies, adding an estimated KRW 150 to 200 million in clinical evidence generation costs per product. Companies entering the market must navigate both regulatory tracks simultaneously if their product includes an integrated application platform, effectively doubling compliance timelines and budgets relative to hardware-only market entry.

Local content and clinical data requirements compound the regulatory burden further. MFDS mandates that clinical validation studies submitted in support of SaMD approval include data from Korean patient populations, meaning that global clinical trial data from the United States or European Union is insufficient on its own. The Korea Pharmaceutical and Bio-Pharma Manufacturers Association has estimated that fulfilling this requirement for a single respiratory SaMD product costs between KRW 300 million and KRW 500 million and takes 12 to 18 additional months. Furthermore, NHIS reimbursement listing requires a separate Health Technology Assessment (HTA) submission to the Health Insurance Review and Assessment Service (HIRA), which evaluates cost-effectiveness against existing respiratory management tools, adding a third sequential approval layer before commercial revenues can be generated.

Policy-Created Opportunities in South Korea

The most immediate opportunity is the Ministry of Health and Welfare's planned expansion of the Chronic Disease Management Programme to include 150 additional primary care clinics by end-2025, each of which will be required under updated NHIS contract terms to offer digitally enabled inhaler monitoring to enrolled patients. This expansion creates a procurement wave estimated at KRW 12 billion in device supply contracts over 2025 and 2026 combined. Suppliers already listed on the NHIS Z-503 benefit schedule hold a decisive first-mover advantage in this procurement cycle, as clinics will default to reimbursement-listed products to minimise billing complexity. Manufacturers not yet listed face exclusion from this cohort unless they complete HIRA HTA submissions before the Q3 2025 deadline for next-cycle benefit schedule updates.

A second structural opportunity arises from the Korean government's K-Bio Health Export Initiative, through which the Ministry of Trade, Industry and Energy (MOTIE) provides up to KRW 500 million in export commercialisation grants per company to Korean-origin medical device firms seeking international certification. Smart inhaler hardware manufacturers including Humed and iSens are eligible to leverage this funding to pursue CE marking and FDA 510(k) clearance, effectively receiving government subsidy to scale domestically developed technology for export. This programme runs through 2027 and represents a policy-created funding mechanism that significantly alters the investment calculus for domestic device manufacturers competing with multinational incumbents in the Korean market.

Market at a Glance

Leading Market Participants

• Boehringer Ingelheim Korea
• AstraZeneca Korea
• GlaxoSmithKline Korea
• Adherium
• Propeller Health (ResMed)
• Novartis Korea
• Humed
• iSens
• Teva Pharmaceutical Korea
• 3M Korea

Regulatory and Policy Environment

The primary legislative framework governing smart inhalers in South Korea is the Medical Device Act (Act No. 16438, as amended), administered by the Ministry of Food and Drug Safety. Smart inhalers incorporating electronic adherence sensors and dose counters are classified as Class II medical devices requiring pre-market approval with clinical performance data. The Digital Medical Devices Act (Act No. 17966), which entered full effect in January 2023, introduced a dedicated approval pathway for software-as-a-medical-device components of smart inhaler systems, with MFDS's newly established Digital Medical Device Division as the responsible authority. Compliance requires GMP certification from a MFDS-approved facility, Korean-language labelling, and post-market surveillance reports submitted annually to MFDS's Medical Device Safety Information System. Compared to regional peers, South Korea's framework is more prescriptive than Singapore's HSA Digital Health framework and more bifurcated than Japan's PMDA combination product pathway, imposing higher cumulative compliance costs but offering clearer regulatory certainty once approvals are secured.

The Health Insurance Review and Assessment Service (HIRA) plays a co-determinant regulatory role through its Benefit Coverage Review, which assesses clinical and economic evidence before NHIS reimbursement is granted. Upcoming regulatory changes include MFDS's planned revision of the Digital Medical Device classification criteria, expected in Q2 2026, which is anticipated to introduce a tiered risk-based fast-track for Class I SaMD products with limited clinical decision support functions. Additionally, the National Assembly is reviewing an amendment to the Health and Medical Big Data Act that would mandate real-world data collection from all reimbursed digital health devices by 2027, creating a new post-market surveillance obligation and simultaneously generating a government-mandated interoperability standard that will shape product architecture requirements across the entire smart inhaler market from 2026 onward.

Long-Term Policy Outlook for South Korea Smart Inhalers

By 2032, the South Korean smart inhaler market will be shaped by three converging policy trajectories. The Ministry of Health and Welfare's National Respiratory Disease Management Master Plan, currently in its third iteration covering 2023 to 2027, is expected to be renewed with expanded digital monitoring mandates and increased NHIS budget allocations for connected respiratory devices. KDCA's ongoing air quality crisis response — South Korea recorded 57 high-pollution days in Seoul in 2023, driving a measurable spike in acute respiratory hospital admissions — creates persistent political pressure to fund preventative respiratory management infrastructure, which directly sustains procurement demand for smart inhalers and digital adherence platforms through the forecast period.

The anticipated MFDS fast-track revision in Q2 2026 will materially lower barriers for software-only smart inhaler platforms, enabling a new cohort of domestic health technology startups to enter the SaMD segment without the full 18-to-24-month review cycle. This regulatory relaxation is expected to fragment the software layer of the market and compress margins for existing SaMD incumbents, while simultaneously expanding total addressable market by enabling smaller primary care facilities to deploy digital inhaler management tools previously restricted to large designated hospitals. By 2030, the planned mandatory real-world data submission requirement under the amended Health and Medical Big Data Act will transform smart inhaler manufacturers into active contributors to Korea's national respiratory disease registry, embedding their products structurally within the public health data infrastructure and making delistment from the NHIS benefit schedule politically and administratively difficult to execute.

Market Segmentation

By Product Type

• Smart Metered-Dose Inhalers (MDI)
• Smart Dry Powder Inhalers (DPI)
• Add-On Sensor Devices
• Nebuliser Systems with Connectivity
• Integrated Software Platforms (SaMD)

By Indication

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Allergic Rhinitis
• Other Respiratory Conditions

By End User

• Hospital Respiratory Departments
• Primary Care Clinics
• Home Care Settings
• Public Health Centres
• Telehealth Platforms

By Distribution Channel

• Hospital Procurement (NHIS Contract)
• Retail Pharmacy
• Direct-to-Patient (Digital Prescription)
• Government Public Health Programmes

Frequently Asked Questions

Q1. What regulatory body approves smart inhalers in South Korea and how long does approval take? ▼

The Ministry of Food and Drug Safety (MFDS) is the sole regulatory authority for smart inhaler approval under the Medical Device Act (Act No. 16438). Pre-market review for Class II combination hardware-software devices averages 18 to 24 months, with SaMD components assessed separately by MFDS's Digital Medical Device Division.

Q2. Is NHIS reimbursement available for smart inhalers and how do manufacturers qualify? ▼

NHIS reimbursement for smart inhaler add-on sensors is available under benefit code Z-503, introduced in 2023. Manufacturers must first obtain MFDS device approval, then submit a Health Technology Assessment dossier to HIRA demonstrating clinical and cost-effectiveness before benefit listing is granted.

Q3. What does the Digital Medical Devices Act (Act No. 17966) require for inhaler software applications? ▼

The Digital Medical Devices Act requires inhaler software applications with clinical decision support functions to obtain separate SaMD approval from MFDS, supported by Korean-population clinical data. Compliance also requires annual post-market surveillance reporting to MFDS's Medical Device Safety Information System.

Q4. Are foreign clinical trial data sufficient for MFDS smart inhaler approval? ▼

MFDS requires that clinical validation studies for SaMD products include data from Korean patient populations; global trial data from the US or EU alone is insufficient. Generating Korea-specific clinical evidence adds an estimated KRW 300–500 million in costs and 12 to 18 months to the approval timeline.

Q5. What upcoming regulatory changes will affect market entry strategy before 2027? ▼

MFDS is expected to introduce a tiered fast-track for low-risk Class I SaMD products in Q2 2026, reducing approval timelines for software-only platforms. A planned amendment to the Health and Medical Big Data Act will mandate real-world data submission from all reimbursed digital health devices by 2027, adding new post-market obligations.